HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Medicinal Chemistry

• Publication date

  2017-10-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/0929867324666170207142740PMID 28078999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HDAC10 promotes lung cancer proliferation via AKT phosphorylation

  2016cited by this paper
• Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach

  2016cited by this paper
• Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

  2016cited by this paper
• Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies.

  2016cited by this paper
• A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.

  2016cited by this paper
• Functional Analysis of Histone Deacetylase 11 (HDAC11).

  2016cited by this paper
• Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

  2016cited by this paper
• Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

  2015cited by this paper
• Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

  2015cited by this paper
• Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7–HMGA2–Cyclin A2 Pathway

  2015cited by this paper
• Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

  2015cited by this paper
• TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells

  2015cited by this paper
• Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

  2015cited by this paper
• Histone Deacetylase 10 Regulates DNA Mismatch Repair and May Involve the Deacetylation of MutS Homolog 2*

  2015cited by this paper
• HDAC4 Regulates Muscle Fiber Type-Specific Gene Expression Programs

  2015cited by this paper
• Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

  2015cited by this paper
• SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

  2015cited by this paper
• Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

  2015cited by this paper
• Class IIa HDACs – new insights into their functions in physiology and pathology

  2015cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis

  2014cited by this paper
• Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer

  2014cited by this paper
• Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression

  2014cited by this paper
• Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells.

  2014cited by this paper
• Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

  2014cited by this paper
• Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

  2014cited by this paper
• A draft map of the human proteome

  2014cited by this paper
• Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.

  2014cited by this paper
• Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

  2014cited by this paper
• Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment

  2014cited by this paper
• Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

  2014cited by this paper
• Prospective randomized double‐blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO‐AB 31/05)

  2014cited by this paper
• Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells

  2014cited by this paper
• Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

  2014cited by this paper
• Histone deacetylase 10 promotes autophagy-mediated cell survival

  2013cited by this paper
• Role of systemic chemotherapy in urothelial urinary bladder cancer.

  2013cited by this paper
• Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers

  2013cited by this paper
• Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation

  2013cited by this paper
• Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.

  2013cited by this paper
• HDAC6: physiological function and its selective inhibitors for cancer treatment.

  2013cited by this paper
• Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma

  2013cited by this paper
• HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

  2013cited by this paper
• HDAC11 is a novel drug target in carcinomas

  2013cited by this paper
• Type I IFN Inhibits Innate IL-10 Production in Macrophages through Histone Deacetylase 11 by Downregulating MicroRNA-145

  2013cited by this paper
• The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts.

  2013cited by this paper
• Beside the MEF2 axis: unconventional functions of HDAC4.

  2013cited by this paper
• Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.

  2013cited by this paper
• Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas

  2013cited by this paper
• Histone deacetylase 5 regulates glucose uptake and insulin action in muscle cells.

  2012cited by this paper
• Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies

  2012cited by this paper
• Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression

  2012cited by this paper
• Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.

  2012cited by this paper
• Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.

  2012cited by this paper
• Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis

  2011cited by this paper
• Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer

  2011cited by this paper
• Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

  2011cited by this paper
• Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells

  2011cited by this paper
• Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility

  2011cited by this paper
• Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis

  2011cited by this paper
• HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.

  2011cited by this paper
• Histone Deacetylases 9 and 10 Are Required for Homologous Recombination*

  2011cited by this paper
• HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro

  2011cited by this paper
• S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

  2011cited by this paper
• [Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?].

  2010cited by this paper
• Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

  2010cited by this paper
• Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays.

  2010cited by this paper
• Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.

  2010cited by this paper
• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  2010cited by this paper
• Inhibition of bladder tumour growth by histone deacetylase inhibitor

  2010cited by this paper
• Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells

  2010cited by this paper
• Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.

  2010cited by this paper
• Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

  2009cited by this paper
• HDAC family: What are the cancer relevant targets?

  2009cited by this paper
• Class IIa histone deacetylases: conducting development and differentiation.

  2009cited by this paper
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

  2009cited by this paper
• The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

  2009cited by this paper
• A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.

  2009cited by this paper
• The many roles of histone deacetylases in development and physiology: implications for disease and therapy

  2009cited by this paper
• Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction

  2009cited by this paper
• Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.

  2009cited by this paper
• Chromosomal instability in bladder cancer

  2008cited by this paper
• MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

  2008cited by this paper
• HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.

  2008cited by this paper
• Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

  2007cited by this paper
• Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells

  2007cited by this paper
• Class IIa histone deacetylases: regulating the regulators

  2007cited by this paper
• Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.

  2007cited by this paper
• Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

  2007cited by this paper
• Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells

  2006cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest

  2006cited by this paper
• Understanding urothelial carcinoma through cancer pathways

  2006cited by this paper
• Increased Expression of EZH2, a Polycomb Group Protein, in Bladder Carcinoma

  2005cited by this paper
• Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

  2005cited by this paper
• Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder

  2005cited by this paper
• The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo

  2005cited by this paper
• Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

  2003cited by this paper
• Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR.

  2002cited by this paper
• FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

  2002cited by this paper
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

  2000cited by this paper

• Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis.

  2025cites this paper
• Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next-generation antibody-drug conjugates (Review)

  2025cites this paper
• HDAC2 as a therapeutic target in bladder cancer: insights into the altered epigenetic regulation and lysine lactylation

  2025cites this paper
• NF‐κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma

  2025cites this paper
• ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids

  2025cites this paper
• Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence

  2024influential citation
• Transcriptome-Based Network Analysis Related to Histone Deacetylase Genes and Identified EMP1 as a Potential Biomarker for Prognosis in Bladder Cancer.

  2024cites this paper
• Ginsenoside Rh4 inhibits breast cancer growth through targeting histone deacetylase 2 to regulate immune microenvironment and apoptosis.

  2023cites this paper
• Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment.

  2023cites this paper
• Epigenetic Priming and Development of New Combination Therapy Approaches.

  2023cites this paper
• Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling

  2023cites this paper
• Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC)

  2022cites this paper
• Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

  2022cites this paper
• The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence

  2022cites this paper
• Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment

  2021cites this paper
• Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells

  2021cites this paper
• Molecular Characterization and Clinical Relevance of Lysine Acetylation Regulators in Urological Cancers

  2021cites this paper
• Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma

  2021cites this paper
• Targeting chromatin remodelers in urological tumors

  2020cites this paper
• Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment

  2020cites this paper
• Epigenetics of Urological Cancers

  2019cites this paper
• Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

  2019influential citation
• HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition

  2019influential citation
• Epigenetic Treatment Options in Urothelial Carcinoma.

  2018cites this paper
• Effects of novel HDAC inhibitors on urothelial carcinoma cells

  2018cites this paper
• Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

  2018cites this paper
• Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

  2018cites this paper
• Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance

  2018cites this paper